Q3 2022 Results

Company overview Financial performance Cardiovascular Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Immunology Neuroscience Oncology Cosentyx® - IL-17A inhibitor Cosentyx®Ⓡ - IL-17A inhibitor NCT04181762 SELUNE (CAIN457Q12301) Indication Lupus Nephritis Phase Phase 3 NCT04930094 GCAPTAIN (CAIN457R12301) Indication Phase Giant cell arteritis Phase 3 Patients 460 Patients 348 Primary Proportion of subjects achieving protocol-defined CRR Outcome Primary Outcome Number of participants with sustained remission Measures Measures Arms Secukinumab 300 mg s.c. Intervention Placebo s.c. Target Patients Patients with active lupus nephritis (ISN/RPS Class III or IV, with or without co-existing class V features) Target Patients Experimental: Secukinumab 300 mg Placebo Comparator: Placebo Patients with Giant Cell Arteritis (GCA) Primary 2025 Arms Intervention Read-out Milestone(s) 2026 Publication 2026 Read-out Milestone(s) Final 2026 Publication TBD 52 Investor Relations | Q3 2022 Results References Abbreviations Other NOVARTIS | Reimagining Medicine

View entire presentation